Studies on the involvement of the exopolysaccharide produced by cystic fibrosis-associated isolates of the Burkholderia cepacia complex in biofilm formation and in persistence of respiratory infections

Journal of Clinical Microbiology
M V CunhaI Sá-Correia

Abstract

Bacteria belonging to the Burkholderia cepacia complex (BCC) are important opportunistic pathogens that lead to respiratory infections in patients with cystic fibrosis (CF). The clinical outcome following colonization with BCC bacteria is highly variable, and so far, unpredictable. A large percentage (80 to 90%) of BCC isolates from CF patients produce the exopolysaccharide (EPS) cepacian, which has been hypothesized to play a role in the colonization and persistence of these bacteria in the CF lung. In this work, we demonstrate that although it is not required for the initiation of biofilm formation, cepacian plays a role in the establishment of thick biofilms. This conclusion was based on a comparison of the abilities of EPS-defective mutants derived from a B. cepacia mucoid CF isolate by random plasposon insertion mutagenesis and the ability of the parental strain to form biofilms. However, the systematic characterization of 108 CF isolates, corresponding to 15 distinct strains, indicated that other strain-dependent factors are also involved in the development of thick, mature biofilms. The isolates examined belonged to the species B. cepacia, B. multivorans, B. cenocepacia, and B. stabilis and were obtained during a 7-year ...Continue Reading

References

Feb 1, 1984·The Journal of Pediatrics·A IslesH Levison
Jan 1, 1994·Journal of Basic Microbiology·D G Allison, M J Goldsbrough
Apr 1, 1993·Journal of Clinical Microbiology·G Y LarsenJ L Burns
Dec 1, 1996·Journal of Medical Microbiology·J R GovanP Vandamme
Mar 31, 1999·Proceedings of the National Academy of Sciences of the United States of America·F H Yildiz, G K Schoolnik
Apr 7, 1999·The Journal of Infectious Diseases·A HolmesR Goldstein
May 21, 1999·Science·J W CostertonE P Greenberg
Nov 17, 1999·Molecular Microbiology·P I Watnick, R Kolter
Apr 4, 2000·Microbiology·K D XuP S Stewart
Apr 8, 2000·FEMS Microbiology Letters·S CérantolaH Montrozier
Jul 13, 2000·Biochemical and Biophysical Research Communications·P CescuttiI Sá-Correia
Sep 28, 2000·Biochemical and Biophysical Research Communications·J A RichauI Sá-Correia
May 4, 2001·The European Respiratory Journal·A M JonesA K Webb
Jul 21, 2001·Lancet·P S Stewart, J W Costerton
Aug 22, 2001·Journal of Bacteriology·M HentzerM R Parsek
Jul 23, 2002·Journal of Medical Microbiology·Eshwar MahenthiralingamPeter Vandamme
Sep 25, 2002·Journal of Bacteriology·Barbara-Ann D ConwayDavid P Speert
Jun 7, 2003·Molecular Microbiology·Mikkel KlausenTim Tolker-Nielsen
Jun 18, 2003·Proceedings of the National Academy of Sciences of the United States of America·Daniel J WozniakMatthew R Parsek
Sep 6, 2003·Journal of Clinical Microbiology·Mónica V CunhaIsabel Sá-Correia
Nov 26, 2003·Biochemical and Biophysical Research Communications·Leonilde M MoreiraIsabel Sá-Correia

❮ Previous
Next ❯

Citations

Aug 19, 2011·Microbial Ecology·Zulma Rocío Suárez-MorenoVittorio Venturi
Apr 15, 2010·Applied Microbiology and Biotechnology·Jorge H LeitãoLeonilde M Moreira
Oct 15, 2011·Applied Microbiology and Biotechnology·Silvia BazziniGiovanna Riccardi
Apr 26, 2007·Current Microbiology·Dianella Savoia, Mario Zucca
Jul 5, 2008·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·J H LeitãoI Sá-Correia
Dec 29, 2012·Proceedings of the National Academy of Sciences of the United States of America·Charles C TraverseVaughn S Cooper
Oct 12, 2005·Current Opinion in Pulmonary Medicine·John J Lipuma
Mar 9, 2010·Acta Crystallographica. Section F, Structural Biology and Crystallization Communications·Joana RochaCarlos Frazão
Oct 11, 2011·Applied and Environmental Microbiology·Nandadeva YakandawalaSrinivasa Madhyastha
Jul 21, 2010·Infection and Immunity·Slade A Loutet, Miguel A Valvano
Jun 5, 2013·Journal of Bacteriology·Christian G RamosJorge H Leitão
Jun 14, 2013·Journal of Clinical Microbiology·Nadia EusebioRicardo Araujo
Feb 8, 2008·Journal of Clinical Microbiology·James E A ZlosnikDavid P Speert
Sep 21, 2015·Biotechnology Letters·Shilpi Srivastava, Atul Bhargava
Aug 13, 2013·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·Anne-Sophie MessiaenTom Coenye
Dec 20, 2015·Future Microbiology·Joana R FelicianoJorge H Leitão
May 2, 2008·International Journal of Pharmaceutics·Majed HalwaniAbdelwahab Omri
Dec 17, 2014·Evolution; International Journal of Organic Evolution·Crystal N EllisVaughn S Cooper
Dec 23, 2006·Biochemical and Biophysical Research Communications·Sílvia A SousaJorge H Leitão
Jul 14, 2007·Cellular Microbiology·Silvia A SousaGerd Döring
Sep 3, 2010·International Journal of Microbiology·Sílvia A SousaJorge H Leitão
Jun 20, 2006·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·Emma CaraherSiobhán McClean
Nov 4, 2005·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·Grasiella M V CarvalhoElizabeth A Marques
Apr 20, 2016·Vaccines·Gonzalo A PradenasAlfredo G Torres

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biofilm & Infectious Disease

Biofilm formation is a key virulence factor for a wide range of microorganisms that cause chronic infections.Here is the latest research on biofilm and infectious diseases.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Biofilms

Biofilms are adherent bacterial communities embedded in a polymer matrix and can cause persistent human infections that are highly resistant to antibiotics. Discover the latest research on Biofilms here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.